These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients. Grawe F; Blom F; Winkelmann M; Burgard C; Schmid-Tannwald C; Unterrainer LM; Sheikh GT; Pfitzinger PL; Kazmierczak P; Cyran CC; Ricke J; Stief CG; Bartenstein P; Ruebenthaler J; Fabritius MP; Geyer T Eur Radiol; 2024 Feb; 34(2):1157-1166. PubMed ID: 37624414 [TBL] [Abstract][Full Text] [Related]
14. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970 [TBL] [Abstract][Full Text] [Related]
15. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122 [TBL] [Abstract][Full Text] [Related]
16. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328 [TBL] [Abstract][Full Text] [Related]
17. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model. Alvim R; Nagar K; Das S; Lebdai S; Wong N; Somma A; Hughes C; Thomas J; Monette S; Scherz A; Kim K; Grimm J; Coleman JA Eur Urol Focus; 2021 Mar; 7(2):472-478. PubMed ID: 31227464 [TBL] [Abstract][Full Text] [Related]
18. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer. Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282 [TBL] [Abstract][Full Text] [Related]
19. Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET. Duan H; Davidzon GA; Moradi F; Liang T; Song H; Iagaru A Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4087-4095. PubMed ID: 37555901 [TBL] [Abstract][Full Text] [Related]
20. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience. Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]